Denali Therapeutics Inc (NASDAQ: DNLI) is -22.65% lower on its value in year-to-date trading and has touched a low of $15.45 and a high of $33.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DNLI stock was last observed hovering at around $16.82 in the last trading session, with the day’s loss setting it -0.22%.
Currently trading at $16.60, the stock is -14.21% and -13.50% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing -1.31% at the moment leaves the stock -21.63% off its SMA200. DNLI registered -33.92% loss for a year compared to 6-month loss of -19.34%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -19.18% gain in the last 1 month and extending the period to 3 months gives it a -0.78%, and is -13.41% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.92% over the week and 4.27% over the month.
Denali Therapeutics Inc (DNLI) has around 445 employees, a market worth around $2.31B and $330.53M in sales. Profit margin for the company is -43.94%. Distance from 52-week low is 7.44% and -50.17% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.50%).
The EPS is expected to shrink by -144.22% this year
The shares outstanding are 138.39M, and float is at 112.29M with Short Float at 8.38%.
Denali Therapeutics Inc (DNLI) Insider Activity
The most recent transaction is an insider sale by SATO VICKI L, the company’s Director. SEC filings show that SATO VICKI L sold 1,666 shares of the company’s common stock on Apr 15 ’24 at a price of $18.29 per share for a total of $30471.0. Following the sale, the insider now owns 0.12 million shares.
Denali Therapeutics Inc disclosed in a document filed with the SEC on Apr 01 ’24 that Krognes Steve E. (Director) sold a total of 92,500 shares of the company’s common stock. The trade occurred on Apr 01 ’24 and was made at $20.50 per share for $1.9 million. Following the transaction, the insider now directly holds 47341.0 shares of the DNLI stock.
Still, SEC filings show that on Mar 15 ’24, SATO VICKI L (Director) disposed off 1,666 shares at an average price of $20.10 for $33487.0. The insider now directly holds 119,709 shares of Denali Therapeutics Inc (DNLI).
